PYPL−0.34moodIREN−0.46moodFRO+0.73moodCVX+0.44moodMRVL−0.26moodESTC+0.60moodBNTX−0.73moodAFRM+0.59moodRBRK−0.33moodTM−0.05moodASML−0.04moodDKNG+0.64moodPYPL−0.34moodIREN−0.46moodFRO+0.73moodCVX+0.44moodMRVL−0.26moodESTC+0.60moodBNTX−0.73moodAFRM+0.59moodRBRK−0.33moodTM−0.05moodASML−0.04moodDKNG+0.64mood

MRVL−0.26moodESTC+0.60moodBNTX−0.73moodAFRM+0.59moodRBRK−0.33moodTM−0.05moodASML−0.04moodDKNG+0.64moodGLCNF−0.50moodT+0.32moodPLTR+0.45moodBAC−0.10moodMRVL−0.26moodESTC+0.60moodBNTX−0.73moodAFRM+0.59moodRBRK−0.33moodTM−0.05moodASML−0.04moodDKNG+0.64moodGLCNF−0.50moodT+0.32moodPLTR+0.45moodBAC−0.10mood

RBRK−0.33moodTM−0.05moodASML−0.04moodDKNG+0.64moodGLCNF−0.50moodT+0.32moodPLTR+0.45moodBAC−0.10moodGE+0.75moodULTA−0.04moodAER+0.35moodBWLP+0.47moodRBRK−0.33moodTM−0.05moodASML−0.04moodDKNG+0.64moodGLCNF−0.50moodT+0.32moodPLTR+0.45moodBAC−0.10moodGE+0.75moodULTA−0.04moodAER+0.35moodBWLP+0.47mood

GLCNF−0.50moodT+0.32moodPLTR+0.45moodBAC−0.10moodGE+0.75moodULTA−0.04moodAER+0.35moodBWLP+0.47moodMELI+0.42moodWDAY+0.62moodFLUT+0.59moodADSK+0.31moodGLCNF−0.50moodT+0.32moodPLTR+0.45moodBAC−0.10moodGE+0.75moodULTA−0.04moodAER+0.35moodBWLP+0.47moodMELI+0.42moodWDAY+0.62moodFLUT+0.59moodADSK+0.31mood

GE+0.75moodULTA−0.04moodAER+0.35moodBWLP+0.47moodMELI+0.42moodWDAY+0.62moodFLUT+0.59moodADSK+0.31moodETN+0.55moodNWFL+0.45moodCTVA+0.35moodASMLF−0.04moodGE+0.75moodULTA−0.04moodAER+0.35moodBWLP+0.47moodMELI+0.42moodWDAY+0.62moodFLUT+0.59moodADSK+0.31moodETN+0.55moodNWFL+0.45moodCTVA+0.35moodASMLF−0.04mood

MELI+0.42moodWDAY+0.62moodFLUT+0.59moodADSK+0.31moodETN+0.55moodNWFL+0.45moodCTVA+0.35moodASMLF−0.04moodPD+0.43moodBX−0.35moodGAP+0.69moodFTNT+0.88moodMELI+0.42moodWDAY+0.62moodFLUT+0.59moodADSK+0.31moodETN+0.55moodNWFL+0.45moodCTVA+0.35moodASMLF−0.04moodPD+0.43moodBX−0.35moodGAP+0.69moodFTNT+0.88mood

ETN+0.55moodNWFL+0.45moodCTVA+0.35moodASMLF−0.04moodPD+0.43moodBX−0.35moodGAP+0.69moodFTNT+0.88moodCOST+0.35moodMSFT+0.49moodCYTK−0.72moodUUUU+0.35moodETN+0.55moodNWFL+0.45moodCTVA+0.35moodASMLF−0.04moodPD+0.43moodBX−0.35moodGAP+0.69moodFTNT+0.88moodCOST+0.35moodMSFT+0.49moodCYTK−0.72moodUUUU+0.35mood

PD+0.43moodBX−0.35moodGAP+0.69moodFTNT+0.88moodCOST+0.35moodMSFT+0.49moodCYTK−0.72moodUUUU+0.35moodJNJ+0.58moodJOBY+0.08moodS−0.40moodAPP+0.08moodPD+0.43moodBX−0.35moodGAP+0.69moodFTNT+0.88moodCOST+0.35moodMSFT+0.49moodCYTK−0.72moodUUUU+0.35moodJNJ+0.58moodJOBY+0.08moodS−0.40moodAPP+0.08mood

COST+0.35moodMSFT+0.49moodCYTK−0.72moodUUUU+0.35moodJNJ+0.58moodJOBY+0.08moodS−0.40moodAPP+0.08moodPYPL−0.34moodIREN−0.46moodFRO+0.73moodCVX+0.44moodCOST+0.35moodMSFT+0.49moodCYTK−0.72moodUUUU+0.35moodJNJ+0.58moodJOBY+0.08moodS−0.40moodAPP+0.08moodPYPL−0.34moodIREN−0.46moodFRO+0.73moodCVX+0.44mood

DRTS · Alpha Tau Medical Ltd. — sentiment, insiders, filings

DRTS

DRTSAlpha Tau Medical Ltd.

Discussion

Nothing said here yet.

to join the conversation.

Levy RaphiChief Financial Officer

Sell

2,871

$43.1K

Fri, Aug 21

Mon, Aug 10
3:01 PMYahooAlpha Tau Announces Second Quarter 2026 Financial Results and Provides Corporate Update
Sat, Aug 1
1:16 AMYahooAlpha Tau Medical (DRTS) Is Down 5.7% After Early-Stop Success In Alpha DaRT Combo Trial
Tue, Jul 21
7:30 AMYahooAlpha Tau Reports Positive Data Demonstrating 100% Objective Response Rate and 18.2-Month Median Overall Survival with Alpha DaRT® in Combination with Pembrolizumab in Locally Advanced or Metastatic Head and Neck Cancer, Surpassing the Study's Pre-Specified Threshold for Success
Wed, Jul 15
7:30 AMYahooAlpha Tau Successfully Treats First Immunocompromised Patient with Recurrent Cutaneous Squamous Cell Carcinoma in its ADMIRE Study at Banner MD Anderson Cancer Center
Sat, Jun 27
2:06 PMYahooAlpha Tau Medical’s (DRTS) First International Brain Cancer Use Tests The Breadth Of Its Alpha DaRT Platform
Tue, Jun 23
7:30 AMYahooAlpha Tau Successfully Treats First Recurrent Glioblastoma Patient Outside of the United States with Alpha DaRT® at Hadassah University Medical Center in Israel
Thu, Jun 11
7:30 AMYahooAlpha Tau Receives FDA Clearance to Complete Enrollment in REGAIN Recurrent Glioblastoma Trial and Add Two U.S. Clinical Sites; Early Interim Results Showed 100% Local Disease Control
Wed, Jun 3
9:52 AMstocktwits.comDRTS Stock Shot Up A Whopping 22% Today – Why A $196.5M Prostate Cancer Deal Got Investors Buzzing
7:30 AMYahooAlpha Tau and Tolmar Announce Strategic Collaboration to Bring Alpha DaRT® Therapy to U.S. Urological Cancer Patients
Mon, Jun 1
8:00 AMYahooAlpha Tau Announces Strong Overall Survival Results from Alpha DaRT® Pancreatic Cancer Studies Presented at 2026 ASCO Annual Meeting
Fri, May 29
8:03 AMmarketbeat.comAlpha Tau Medical Sets Up Catalyst-Rich 2026 as Key Cancer Trial Data Nears
Mon, May 18
3:01 PMYahooAlpha Tau Announces First Quarter 2026 Financial Results and Provides Corporate Update